Current directions of biologic therapies in inflammatory bowel disease

Therapeutic Advances in Gastroenterology

Volumn 3, Issue 2, 2010, Pages 99-106

  Reenaers, Catherine ^a   Louis, Edouard ^b   Belaiche, Jacques ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Adalimumab; Certolizumab; Crohn's disease; Inflammatory bowel disease; Infliximab; Natalizumab; Ulcerative colitis; Ustekinumab; Vedolizumab

Indexed keywords

ABT 874; ADALIMUMAB; CERTOLIZUMAB PEGOL; CYTOKINE; INFLIXIMAB; INTEGRIN; INTERLEUKIN 12; INTERLEUKIN 23; NATALIZUMAB; PLACEBO; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 10; TOCILIZUMAB; USTEKINUMAB; VEDOLIZUMAB; VISILIZUMAB;

BIOLOGICAL THERAPY; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; HERPES VIRUS INFECTION; HUMAN; INJECTION SITE REACTION; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 77953397202     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X09356872     Document Type: Review

References (69)

1. Baert, F., Noman, M., Vermeire, S., van Assche, G., D'Haens, G., Carbonez, A. et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601-608.
2. Beaugerie, L., Seksik, P., Nion-Larmurier, I., Gendre, J.P. and Cosnes, J. ( 2006) Predictors of Crohn's disease. Gastroenterology 130: 650-656.
3. Beck, P.L. and Podolsky, D.K. ( 1999) Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 5: 44-60.
4. Berrebi, D., Besnard, M., Fromont-Hankard, G., Paris, R., Mougenot, J.F., de Lagausie, P. et al. (1998) Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease. Am J Pathol 152: 667-672.
5. Bouhnik, Y., Lémann, M., Mary, J.Y., Scemama, G., Taï, R., Matuchansky, C. et al. (1996) Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347: 215-219.
6. Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R. et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's diease: the CHARM trial. Gastroenterology 132 (1): 52-65.
7. Cosnes, J., Cattan, S., Blain, A., Beaugerie, L., Carbonnel, F., Parc, R. et al. (2002) Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 8: 244-250.
8. Cosnes, J., Nion-Larmurier, I., Beaugerie, L., Afchain, P., Tiret, E. and Gendre, J.P. ( 2005) Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54: 237-241.
9. Davidson, N.J., Hudak, S.A., Lesley, R.E., Menon, S., Leach, M.W. and Rennick, D.M. ( 1998) IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 161: 3143-3149.
10. D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H. et al. (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371: 660-667.
11. Ding, C. and Jones, G. ( 2006) Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev Recent Clin Trials 1: 193-200.
12. Faubion Jr, W.A., Loftus Jr, E.V., Harmsen, W.S., Zinsmeister, A.R. and Sandborn, W.J. ( 2002) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 123: 393-395.
13. Feagan, B.G., Greenberg, G.R., Wild, G., Fedorak, R.N., Paré, P., McDonald, J.W. et al. (2005) Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352: 2499-2507.
14. Feagan, B.G., Greenberg, G.R., Wild, G., Fedorak, R.N., Paré, P., McDonald, J.W. et al. (2008) Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 6: 1370-1377.
15. Fedorak, R.N., Gangl, A., Elson, C.O., Rutgeerts, P., Schreiber, S., Wild, G., Hanauer, S.B. et al. (2000) Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119: 1473-1482.
16. Gately, M.K., Renzetti, L.M., Magram, J., Stern, A.S., Adorini, L., Gubler, U. et al. (1998) The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16: 495-521.
17. Ghosh, S., Goldin, E., Gordon, F.H., Malchow, H.A., Rask-Madsen, J., Rutgeerts, P. et al. (2003) Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N Engl J Med 348: 24-32.
18. Gordon, F.H., Hamilton, M.I., Donoghue, S., Greenlees, C., Palmer, T., Rowley-Jones, D. et al. (2002) A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 16: 699-705.
19. Gordon, F.H., Lai, C.W., Hamilton, M.I., Allison, M.C., Srivastava, E.D., Fouweather, M.G. et al. (2001) A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha 4 integrin in active Crohn's disease. Gastroenterology 121: 268-274.
20. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F. et al. (2002) ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541-1549.
21. Hanauer, S.B., Wagner, C.L., Bala, M., Mayer, L., Travers, S., Diamond, R.H. et al. (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2: 542-553.
22. Hoie, O., Wolters, F.L., Riis, L., Bernklev, T., Aamodt, G., Clofent, J. et al. (2007) Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 132: 507-515.
23. Hwang, W.Y. and Foote, J. ( 2005) Immunogenicity of engineered antibodies. Methods 36: 3-10.
24. Hyams, J., Crandall, W., Kugathasan, S., Griffiths, A., Olson, A., Johanns, J. et al. (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132: 863-873.
25. Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A. et al. (2004) A randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126: 989-996.
26. Järnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C. et al. (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128: 1805-1811.
27. Keane, J., Gershon, S., Wise, R.P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W.D. et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-1104.
28. Kornbluth, A. and Sachar, D.B. ( 2004) Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 99: 1371-1385.
29. Korzenik, J.R., Dieckgraefe, B.K., Valentine, J.F., Hausman, D.F. and Gilbert, M.J. Sargramostim in Crohn's Disease Study Group. ( 2005) Sargramostim for active Crohn's disease. N Engl J Med 352: 2193-2201.
30. Kühn, R., Löhler, J., Rennick, D., Rajewsky, K. and Müller, W. ( 1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274.
31. Lémann, M., Mary, J.Y., Colombel, J.F., Duclos, B., Soule, J.C., Lerebours, E. et al. (2005) A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 128: 1812-1818.
32. Lichtenstein, G.R., Feagan, B.G., Cohen, R.D., Salzberg, B.A., Diamond, R.H., Chen, D.M. et al. (2006) Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4: 621-630.
33. Louis, E., Collard, A., Oger, A.F., Degroote, E., Aboul Nasr El Yafi, F.A. et al. (2002) Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 51: 614-615.
34. Mannon, P.J., Fuss, I.J., Mayer, L., Elson, C.O., Sandborn, W.J., Present, D. et al. (2004) Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351: 2069-2079.
35. Mattner, F., Fischer, S., Guckes, S., Jin, S., Kaulen, H., Schmitt, E. et al. (1993) The interleukin-12 subunit p 40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol 23: 2202-2208.
36. Monteleone, G., Biancone, L., Marasco, R., Morrone, G., Marasco, O., Luzza, F. et al. (1997) Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112: 1169-1178.
37. Moore, K.W., de Waal Malefyt, R., Coffman, R.L. and O'Garra, A. ( 2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765.
38. Munkholm, P., Langholz, E., Davidsen, M. and Binder, V. ( 1995) Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 30: 699-706.
39. Neurath, M.F., Fuss, I., Kelsall, B.L., Stüber, E. and Strober, W. ( 1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182: 1281-1290.
40. Parronchi, P., Romagnani, P., Annunziato, F., Sampognaro, S., Becchio, A., Giannarini, L. et al. (1997) Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 150: 823-832.
41. Peyrin-Biroulet, L., Laclotte, C. and Bigard, M.-A. ( 2007) Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 13: 2328-2332.
42. Plevy, S., Salzberg, B., van Assche, G., Regueiro, M., Hommes, D., Sandborn, W. et al. (2007) A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133: 1414-1422.
43. Present, D.H., Rutgeerts, P., Targan, S., Hanauer, S.B., Mayer, L., van Hogezand, R.A. et al. (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398-1405.
44. Reimund, J.M., Wittersheim, C., Dumont, S., Muller, C.D., Kenney, J.S. and Baumann, R. ( 1996) Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 39: 684-689.
45. Reinecker, H.C., Steffen, M., Witthoeft, T., Pflueger, I., Schreiber, S., MacDermott, R.P. et al. (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94: 174-181.
46. Rutgeerts, P., Sandborn, W.J., Feagan, B.G., Reinisch, W., Olson, A., Johanns, J. et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476.
47. Rutgeerts, P., van Assche, G. and Vermeire, S. ( 2004) Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126: 1593-1610.
48. Sandborn, W.J., Feagan, B.G., Fedorak, R.N., Scherl, E., Fleisher, M.R., Katz, S. et al. (2008) A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135: 1130-1141.
49. Sandborn, W.J., Feagan, B.G., Stoinov, S., Honiball, P.J., Rutgeerts, P., Mason, D. et al. (2007 a) PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228-238.
50. Sandborn, W.J., Hanauer, S.B., Katz, S., Safdi, M., Wolf, D.G., Baerg, R.D. et al. (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088-1094.
51. Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Colombel, J.F., Panaccione, R. et al. (2007 b) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146: 829-838.
52. Sandborn, W.J. and Yednock, T.A. ( 2003) Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 98: 2372-2382.
53. Sands, B.E., Anderson, F.H., Bernstein, C.N., Chey, W.Y., Feagan, B.G., Fedorak, R.N. et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876-885.
54. Schmidt, C., Giese, T., Ludwig, B., Mueller-Molaian, I., Marth, T., Zeuzem, S. et al. (2005) Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 11: 16-23.
55. Schreiber, S., Fedorak, R.N., Nielsen, O.H., Wild, G., Williams, C.N., Nikolaus, S. et al. (2000) Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119: 1461-1472.
56. Schreiber, S., Khaliq-Kareemi, M., Lawrance, I.C., Thomsen, O., Hanauer, S.B., McColm, J. et al. (2007) PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357: 239-250.
57. Schreiber, S., Rutgeerts, P., Fedorak, R.N., Khaliq-Kareemi, M., Kamm, M.A., Boivin, M. et al. e (2005) CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129: 807-818.
58. Shen, C., van Assche, G.V., Colpaert, S., Maerten, P., Geboes, K., Rutgeerts, P. et al. (2005) Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21: 251-258.
59. Shen, C., van Assche, G., Rutgeerts, P. and Ceuppens, J.L. ( 2006) Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 12: 22-28.
60. Sinha, A., Nightingale, J., West, K.P., Berlanga-Acosta, J. and Playford, R.J. ( 2003) Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349: 350-357.
61. Stevens, C., Walz, G., Singaram, C., Lipman, M.L., Zanker, B., Muggia, A. et al. (1992) Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 37: 818-826.
62. Targan, S.R., Hanauer, S.B., van Deventer, S.J., Mayer, L., Present, D.H., Braakman, T. et al. (1997) A short-term study of chimeric monoclonal antibody cA 2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA 2 Study Group. N Engl J Med 337: 1029-1035.
63. ten Hove, T., van Montfrans, C., Peppelenbosch, M.P. and van Deventer, S.J. ( 2002) Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50: 206-211.
64. Trinder, M.W. and Lawrance, I.C. (2009) Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 24 (7): 1160-1162.
65. van Assche, G., van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M. et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362-368.
66. van den Brande, J.M., Braat, H., van den Brink, G.R., Versteeg, H.H., Bauer, C.A., Hoedemaeker, I. et al. (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124: 1774-1785.
67. Wolters, F.L., Russel, M.G., Sijbrandij, J., Schouten, L.J., Odes, S., Riis, L. et al. (2006) Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 55: 1069-1070.
68. Yen, D., Cheung, J., Scheerens, H., Poulet, F., McClanahan, T., McKenzie., B,. et al. (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116: 1310-1316.
69. Yousry, T.A., Major, E.O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J. et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (9): 924-933.